Annals of Urologic Oncology (AUO, Ann Urol Oncol, p-ISSN: 2617-7765, e-ISSN: 2617-7773) is a peer-reviewed, international scientific journal committed to disseminating high-caliber research in the field of urologic oncology. The journal publishes original research addressing the molecular, cellular and clinical aspects of urologic tumors. The journal’s scope encompasses studies on risk assessment, cellular and molecular characterization, prevention, detection, diagnosis, and treatment strategies aimed at improving patient outcomes in urologic oncology. The journal primarily focusses on three subjects: bladder, prostate and kidney cancer. Additionally, studies on adrenal tumors, testicular cancer, and carcinoma of the penis are also welcomed.
Indexing Google Scholar, ResearchGate, DOAJ
Current Issue Volume 8 Issue 4, 2025 >>
Editorial board
Editors-in-Chief:
Sanjay Gupta, Ph.D.----------Case Western Reserve University & UH Cleveland Medical Center, Cleveland, OH, USA.
Jae Y. Ro, Ph.D.---------------Houston Methodist Hospital and Weill Medical College of Cornell University, Houston, TX, USA. More >>
Testicular carcinoma is the most common solid tumor in young male patients. Despite a high rate of survival, current treatments come with significant ...
Aadhira Aiyar, Alina Roos
REVIEW | 30 Nov 2025
Adrenocortical carcinoma (ACC) is a rare and highly aggressive endocrine cancer type, posing significant clinical challenges due to its diverse molecu ...
Declan Moore, Wayway Li
REVIEW | 20 Dec 2025
High Mobility Group Box 1 (HMGB1) is non-histone chromatin protein that plays important roles in maintaining nuclear architecture, transcriptional mod ...
Betty Alex
REVIEW | 22 Dec 2025
Prostate-specific membrane antigen (PSMA) positron emission tomography–computed tomography (PET-CT), has become the benchmark imaging tool in the mana ...
Theo Smith, Mia Harper
REVIEW | 28 Dec 2025
Urothelial carcinoma of the bladder (UBC) is a heterogeneous disease from the clinicopathologic and molecular standpoint and presents clinical managem ...
Amr Abd-Elraheem Abdo, Ahmed Mohamed Kamel
REVIEW | 10 Dec 2025
Background Primary renal leiomyosarcoma (LMS) is an exceptionally rare malignant mesenchymal tumor, constituting <1.5% of all primary renal malignanci ...
Rashi Maheshwari, Shikhar Chohan ... Sufian Zaheer
CASE REPORT | 23 Sep 2025
Submit Manuscript
